05-23-0101 Angiotensin II, Human - CAS 4474-91-3 - Calbiochem

05-23-0101
Cenu nelze zjistit
Minimum Quantity needs to be mulitiple of
S dokončenou objednávkou Další informace
Ušetřili jste ()
 
Vyžádat nacenění
Omezená dostupnostOmezená dostupnost
Na skladě 
Přerušeno
Dostupné omezené množství
Dostupnost bude potvrzena
    Remaining : Will advise
      Remaining : Will advise
      Bude poskytnuto
      Kontaktujte Zákaznický servis
      Contact Customer Service
      Zobrazit ceny a dostupnost
      Klikněte pro vytištění této stránky

      Přehled

      Replacement Information

      Tabulka spec. kláve

      Empirical FormulaCAS #
      C₅₀H₇₁N₁₃O₁₂ 4474-91-3

      Ceny a dostupnost

      Katalogové čísloDostupnost Balení ks/bal. Cena Množství
      05-23-0101-1MG
      Zjišťuji dostupnost...
      Omezená dostupnostOmezená dostupnost
      Na skladě 
      Přerušeno
      Dostupné omezené množství
      Dostupnost bude potvrzena
        Remaining : Will advise
          Remaining : Will advise
          Bude poskytnuto
          Kontaktujte Zákaznický servis
          Contact Customer Service

          Plastová ampulka 1 mg
          Zjišťuji cenu...
          Cenu nelze zjistit
          Minimum Quantity needs to be mulitiple of
          S dokončenou objednávkou Další informace
          Ušetřili jste ()
           
          Vyžádat nacenění
          05-23-0101-25MG
          Zjišťuji dostupnost...
          Omezená dostupnostOmezená dostupnost
          Na skladě 
          Přerušeno
          Dostupné omezené množství
          Dostupnost bude potvrzena
            Remaining : Will advise
              Remaining : Will advise
              Bude poskytnuto
              Kontaktujte Zákaznický servis
              Contact Customer Service

              Skleněná láhev 25 mg
              Zjišťuji cenu...
              Cenu nelze zjistit
              Minimum Quantity needs to be mulitiple of
              S dokončenou objednávkou Další informace
              Ušetřili jste ()
               
              Vyžádat nacenění
              05-23-0101-5MG
              Zjišťuji dostupnost...
              Omezená dostupnostOmezená dostupnost
              Na skladě 
              Přerušeno
              Dostupné omezené množství
              Dostupnost bude potvrzena
                Remaining : Will advise
                  Remaining : Will advise
                  Bude poskytnuto
                  Kontaktujte Zákaznický servis
                  Contact Customer Service

                  Plastová ampulka 5 mg
                  Zjišťuji cenu...
                  Cenu nelze zjistit
                  Minimum Quantity needs to be mulitiple of
                  S dokončenou objednávkou Další informace
                  Ušetřili jste ()
                   
                  Vyžádat nacenění
                  Description
                  OverviewPlays an important role in the regulation of blood pressure. Stimulates the release of aldosterone from the adrenal gland. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Also elicits an increase in voltage-dependent delayed rectifier K+ current in neurons. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates p60c-src as well as ERK1/2, JNK, and p38 MAP Kinase in vascular smooth muscle cells.
                  Catalogue Number05-23-0101
                  Brand Family Calbiochem®
                  SynonymsDRVYIHPF
                  References
                  ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
                  Natarajan, R., et al. 1999. Hypertension 33, 378.
                  Mazzolai, L., et al. 1998. Hypertension 31, 1324.
                  Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
                  Ishida, M., et al. 1995. Circ. Res. 77, 1053.
                  Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
                  Product Information
                  CAS number4474-91-3
                  ATP CompetitiveN
                  FormWhite to off-white solid
                  Hill FormulaC₅₀H₇₁N₁₃O₁₂
                  Chemical formulaC₅₀H₇₁N₁₃O₁₂
                  Hygroscopic Hygroscopic
                  ReversibleN
                  Sold on the basis of peptide contentY
                  Applications
                  Biological Information
                  Primary Targetadenylate cyclase activity
                  Purity≥98% by HPLC
                  Physicochemical Information
                  Cell permeableN
                  Peptide ContentY
                  Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
                  Dimensions
                  Materials Information
                  Toxicological Information
                  Safety Information according to GHS
                  RTECSBW2165000
                  Safety Information
                  Product Usage Statements
                  Storage and Shipping Information
                  Ship Code Ambient Temperature Only
                  Toxicity Standard Handling
                  Storage -20°C
                  Hygroscopic Hygroscopic
                  Do not freeze Ok to freeze
                  Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
                  Packaging Information
                  Transport Information
                  Supplemental Information
                  Specifications

                  Documentation

                  MSDS

                  Title

                  Safety Data Sheet (SDS) 

                  Certificates of Analysis

                  TitleLot Number
                  05-23-0101

                  References

                  Přehled odkazů
                  Zhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
                  Natarajan, R., et al. 1999. Hypertension 33, 378.
                  Mazzolai, L., et al. 1998. Hypertension 31, 1324.
                  Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
                  Ishida, M., et al. 1995. Circ. Res. 77, 1053.
                  Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
                  Data Sheet

                  Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

                  Revision12-May-2008 JSW
                  SynonymsDRVYIHPF
                  DescriptionFunctions in blood pressure maintenance. Stimulates the release of aldosterone from the adrenal gland. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates pp60c-src in vascular smooth muscle cells. Inhibits adenylate cyclase activity in spontaneously hypertensive rats.
                  FormWhite to off-white solid
                  CAS number4474-91-3
                  RTECSBW2165000
                  Chemical formulaC₅₀H₇₁N₁₃O₁₂
                  Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
                  Purity≥98% by HPLC
                  Solubility5% acetic acid (1 mg/ml) or H₂O (1 mg/ml)
                  Storage -20°C
                  Hygroscopic
                  Do Not Freeze Ok to freeze
                  Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
                  Toxicity Standard Handling
                  Merck USA index14 651
                  ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
                  Natarajan, R., et al. 1999. Hypertension 33, 378.
                  Mazzolai, L., et al. 1998. Hypertension 31, 1324.
                  Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
                  Ishida, M., et al. 1995. Circ. Res. 77, 1053.
                  Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.